Medical gear maker Getinge tops core profit forecast in Q4, boosting shares

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Posted By Global Banking and Finance Review

Posted on January 28, 2025

Medical gear maker Getinge tops core profit forecast in Q4, boosting shares

(Reuters) -Swedish medical equipment maker Getinge reported fourth-quarter core earnings above market expectations on Tuesday, supported by solid growth in order intake and sales across its regions.

Its shares were up around 8% by 0858 GMT, among top performers on Europe's benchmark STOXX 600 index.

Getinge said growth was particularly strong in ventilators. Consumables in extracorporeal life support in its main Acute Care Therapies unit and sterile transfer in the Life Science arm also showed solid performance.

Acute Care Therapies, which makes heart and intensive care products, generated more than half of the group's sales in 2024. Life Science, which provides equipment, technical expertise and consultations to prevent contamination in pharmaceutical and medical device production, made up 13% of them.

Paragonix Technologies, which Getinge bought in the third quarter of last year, also posted "impressive growth" in the fourth quarter, it said.

"Despite geopolitical uncertainties and potential trade barriers, our industry is likely to remain relatively stable, driven by long-term healthcare needs and hospitals' willingness to invest," Getinge said in a statement, forecasting a 2-5% organic rise in 2025 sales.

Asked about possible U.S. health care policy changes under President Donald Trump, CEO Mattias Perjos told Reuters it was too early to say how they might affect Getinge, which makes more than a third of its sales in the United States.

Tariffs should not affect the company as the medical technology sector is not among Trump's targets, Perjos added.

Getinge's adjusted operating earnings before amortisation (EBITA) rose 63% to 2.14 billion Swedish crowns ($194.65 million) in the fourth quarter, while analysts were expecting 1.58 billion crowns in a company-provided consensus.

Structural and cost efficiency measures boosted the quarterly operating margin, Getinge said. Its adjusted EBITA margin rose to 19.4% from 13.3% year ago.

The company proposed a dividend of 4.60 crowns per share for 2024, up from the 4.40 crowns paid last year but slightly below analysts' average estimate of 4.63 crowns, according to LSEG's IBES data.

($1 = 10.9943 Swedish crowns)

(Reporting by Marta Frąckowiak in Gdansk; Editing by Milla Nissi)

Recommended for you